Brighton Jones LLC Sells 247 Shares of DexCom, Inc. (NASDAQ:DXCM)

Brighton Jones LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,636 shares of the medical device company’s stock after selling 247 shares during the quarter. Brighton Jones LLC’s holdings in DexCom were worth $311,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of DXCM. Team Hewins LLC lifted its holdings in DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC boosted its holdings in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. grew its stake in DexCom by 6.0% in the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in DexCom by 0.3% during the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock worth $5,801,000 after purchasing an additional 105 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent research reports. Piper Sandler reissued an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday. Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Finally, Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $73.44 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a market cap of $29.21 billion, a PE ratio of 47.38, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The business has a 50-day simple moving average of $70.11 and a two-hundred day simple moving average of $98.24.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, equities analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.